Effects of fermented ginseng on memory impairment and β-amyloid reduction in Alzheimer's disease experimental models

Journal of Ginseng Research

Volumn 37, Issue 1, 2013, Pages 100-107

  Kim, Joonki ^a   Kim, Sung Hun ^a   Lee, Deuk Sik ^b,c   Lee, Dong Jin ^c   Kim, Soo Hyun ^c   Chung, Sungkwon ^d   Yang, Hyun Ok ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Hanzhong University   (South Korea)

^c Institute of Life Science   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Alzheimer's disease; Animal model; Beta amyloid; Fermented ginseng; Panax ginseng

Indexed keywords

ANIMALIA; MUS; MUS MUSCULUS; PANAX GINSENG;

EID: 84872225844     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.5142/jgr.2013.37.100     Document Type: Article

References (35)

1. Chauhan NB, Sandoval J. Amelioration of early cognitive deficits by aged garlic extract in Alzheimer's transgenic mice. Phytother Res 2007;21:629-640.
2. Heo JH, Lee ST, Oh MJ, Park HJ, Shim JY, Chu K, Kim MH: Improvement of cognitive deficit in Alzheimer's disease patients by long term treatment with Korean red ginseng. J Ginseng Res 2011; 35:457-461.
3. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 2000;924:17-25.
4. Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004;6:1054-1061.
5. Yoon SS, Jo SA. Mechanisms of amyloid-β peptide clearance: potential therapeutic targets for Alzheimer's disease. Biomol Ther (Seoul) 2012;20:245-255.
6. Yeo HB, Yoon HK, Lee HJ, Kang SG, Jung KY, Kim L: Effects of Korean red ginseng on cognitive and motor function: a double-blind, randomized, placebo-controlled trial. J Ginseng Res 2012; 36:190-197.
7. Jesky R, Hailong C. Are herbal compounds the next frontier for alleviating learning and memory impairments? An integrative look at memory, dementia and the promising therapeutics of traditional chinese medicines. Phytother Res 2011;25:1105-1118.
8. Zhao H, Li Q, Zhang Z, Pei X, Wang J, Li Y. Long-term ginsenoside consumption prevents memory loss in aged SAMP8 mice by decreasing oxidative stress and upregulating the plasticity-related proteins in hippocampus. Brain Res 2009;1256:111-122.
9. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Abeta(25-35)-induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, A metabolite of protopanaxadiol-type saponins. Neuropsycho pharmacology 2004;29:860-868.
10. Sano M, Grossman H, Van Dyk K. Preventing Alzheimer's disease: separating fact from fiction. CNS Drugs 2008;22:887-902.
11. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999;58:1685-1693.
12. Trinh HT, Han SJ, Kim SW, Lee YC, Kim DH. Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng. J Microbiol Biotechnol 2007;17:1127-1133.
13. Jeon WJ, Oh JS, Park MS, Ji GE. Anti-hyperglycemic effect of fermented ginseng in type 2 diabetes mellitus mouse model. Phytother Res 2012; Epub ahead of print.
14. Park JW, Lee JC, Ann S, Seo DW, Choi WS, Yoo YH, Park SK, Choi JY, Um SH, Ahn SH et al. A fermented ginseng extract, BST204, inhibits proliferation and motility of human colon cancer cells. Biomol Ther (Seoul) 2011;19:211-217.
15. Yuan HD, Chung SH. Fermented ginseng protects streptozotocin-induced damage in rat pancreas by inhibiting nuclear factor-kappaB. Phytother Res 2010;24 Suppl 2:S190-S195.
16. Seo JY, Lee JH, Kim NW, Her E, Chang SH, Ko NY, Yoo YH, Kim JW, Seo DW, Han JW et al. Effect of a fermented ginseng extract, BST204, on the expression of cyclooxygenase-2 in murine macrophages. Int Immunopharmacol 2005;5:929-936.
17. Jung JW, Kang HR, Ji GE, Park MS, Song WJ, Kim MH, Kwon JW, Kim TW, Park HW, Cho SH et al. Therapeutic effects of fermented red ginseng in allergic rhinitis: a randomized, double-blind, placebo-controlled study. Allergy Asthma Immunol Res 2011;3:103-110.
18. Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, Kim TW. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc Natl Acad Sci U S A 2006;103:19524-19529.
19. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 2007;180:139-145.
20. Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys Acta 2012;1822:286-292.
21. Shi YQ, Huang TW, Chen LM, Pan XD, Zhang J, Zhu YG, Chen XC. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 2010;19:977-989.
22. Wang YH, Du GH. Ginsenoside Rg1 inhibits betasecretase activity in vitro and protects against Abetainduced cytotoxicity in PC12 cells. J Asian Nat Prod Res 2009;11:604-612.
23. Zhao R, Zhang Z, Song Y, Wang D, Qi J, Wen S. Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3β pathway in ginsenoside Rb1's attenuation of beta-amyloid-induced neurotoxicity and tau phosphorylation. J Ethnopharmacol 2011;133:1109-1116.
24. Wang Y, Liu J, Zhang Z, Bi P, Qi Z, Zhang C. Anti-neuro-inflammation effect of ginsenoside Rbl in a rat model of Alzheimer disease. Neurosci Lett 2011;487:70-72.
25. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:411-422.
26. Fischer W, Chen KS, Gage FH, Bjorklund A. Progressive decline in spatial learning and integrity of forebrain cholinergic neurons in rats during aging. Neurobiol Aging 1992;13:9-23.
27. Tariot PN, Patel SV, Cox C, Henderson RE. Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology (Berl) 1996;125:50-56.
28. Giacobini E. The cholinergic system in Alzheimer disease. Prog Brain Res 1990;84:321-332.
29. Bejar C, Wang RH, Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 1999;383:231-240.
30. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 1991;14:220-223.
31. Epis R, Gardoni F, Marcello E, Genazzani A, Canonico PL, Di Luca M. Searching for new animal models of Alzheimer's disease. Eur J Pharmacol 2010;626:57-63.
32. Woodruff-Pak DS. Animal models of Alzheimer's disease: therapeutic implications. J Alzheimers Dis 2008;15:507-521.
33. Sharma S, Rakoczy S, Brown-Borg H. Assessment of spatial memory in mice. Life Sci 2010;87:521-536.
34. Galimberti D, Scarpini E. Alzheimer's disease: from pathogenesis to disease-modifying approaches. CNS Neurol Disord Drug Targets 2011;10:163-174.
35. Evin G, Barakat A, Masters CL. BACE: therapeutic target and potential biomarker for Alzheimer's disease. Int J Biochem Cell Biol 2010;42:1923-1926.